A Phase I, Double-Blind, Double-Dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-State and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-State on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers.

Trial Profile

A Phase I, Double-Blind, Double-Dummy, Randomized, Placebo Controlled and Active Controlled Trial to Evaluate the Effect of TMC278 25 mg Daily at Steady-State and the Effect of Efavirenz (EFV) 600 mg Daily at Steady-State on the QT/QTc Interval, in 2 Randomized Panels of Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Mar 2010

At a glance

  • Drugs Efavirenz; Moxifloxacin; Rilpivirine
  • Indications Bacterial infections; HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 08 Dec 2009 Results will be presented at the 12th European AIDS Conference.
    • 18 Apr 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top